MENU
RDY
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

RDY stock forecast, quote, news & analysis

Dr... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
RDY
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for RDY with price predictions
Oct 28, 2026

RDY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for RDY turned positive on October 09, 2026. Looking at past instances where RDY's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RDY as a result. In 42 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.

The 10-day moving average for RDY crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.

Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in 154 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

The Aroon Indicator entered an Uptrend today. In 89 of 243 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (8.801). P/E Ratio (0.356) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.152). Dividend Yield (0.021) settles around the average of (0.044) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (178.797).

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

RDY paid dividends on August 05, 2026

Dr. Reddy's Laboratories Ltd RDY Stock Dividends
А quarterly dividend of $0.07 per share was paid with a record date of August 05, 2026, and an ex-dividend date of July 24, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.34B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 6%. TKNO experienced the highest price growth at 34%, while UPC experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 9% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 59
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
RDY's MACD Histogram crosses above signal line